CLDN4 and familial pancreatic carcinoma: Further bioconjugation with pancreatic cancer-specific monoclonal antibodies, such as anti claudin-4, to the functionalized InP/ZnS QDs, allowed specific in vitro targeting of pancreatic cancer cell lines.